Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide.
about
Quality of life and hepatocellular carcinomaSystemic therapy of hepatocellular carcinoma: current status and future perspectivesThe GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets.Everolimus and pasireotide for advanced and metastatic hepatocellular carcinomaA Phase II Study of Long-Acting Octreotide in Patients With Advanced Hepatocellular Carcinoma and CLIP Score of 3 or HigherSomatostatin receptor subtypes 2 and 5 are associated with better survival in operable hepatitis B-related hepatocellular carcinoma following octreotide long-acting release treatment.Octreotide LAR: safety and tolerability issues.Somatostatin analogues in advanced hepatocellular carcinoma: an updated systematic review and meta-analysis of randomized controlled trials.Value of quality of life analysis in liver cancer: A clinician's perspectiveSomatostatin and opioid receptors do not regulate proliferation or apoptosis of the human multiple myeloma U266 cells.Octreotide and hepatocellular carcinoma.Inhibition of early preneoplastic events in the rat liver by the somatostatin analog lanreotide.Somatostatin and CXCR4 chemokine receptor expression in hepatocellular and cholangiocellular carcinomas: tumor capillaries as promising targets.Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight.
P2860
Q26825504-8F566C12-E234-4BA9-A6BD-137054726D5CQ26865844-78D98069-7252-4AE2-BE83-4A722CD0CE24Q34182483-3F101DCA-A05B-409E-AB96-4711CB8F5516Q35806395-D043E6B5-0071-4B14-8D4F-01FC837C586BQ37198606-CAD4E63A-67D1-45EF-A47D-22431F5AA50DQ37211764-B666D9B2-3B65-4D72-BE10-F21458348D91Q37649647-240F2B6A-53BF-47AC-B354-7186BC26848BQ37908974-269947D0-ACB5-46B0-A1D6-9BED9E3C0C65Q38626594-B049E015-FB60-4E41-B46A-AD00EDCE310FQ39842258-95878744-ED66-453E-B380-981D06C8DAC0Q42559355-48EF1D1E-E530-49F8-B057-76BFA87A4612Q46978157-407AF0C0-91C5-4304-975D-B103837C32FCQ47135284-0631D870-104C-4C9F-A873-95B75B4E81ABQ52345488-717BA11C-6AD1-45A3-8345-853FB66CFD6B
P2860
Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Somatostatin receptor expressi ...... d with long-acting octreotide.
@ast
Somatostatin receptor expressi ...... d with long-acting octreotide.
@en
type
label
Somatostatin receptor expressi ...... d with long-acting octreotide.
@ast
Somatostatin receptor expressi ...... d with long-acting octreotide.
@en
prefLabel
Somatostatin receptor expressi ...... d with long-acting octreotide.
@ast
Somatostatin receptor expressi ...... d with long-acting octreotide.
@en
P2093
P2860
P356
P1476
Somatostatin receptor expressi ...... ed with long-acting octreotide
@en
P2093
A Strickland
Australasian Gastro-Intestinal Trials Group (AGITG) Ag0001H Investigators
C Hargreaves
D Crawford
G Macdonald
P2860
P2888
P304
P356
10.1038/SJ.BJC.6603325
P407
P577
2006-09-05T00:00:00Z